期刊
ADOLESCENT HEALTH MEDICINE AND THERAPEUTICS
卷 8, 期 -, 页码 125-135出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/AHMT.S109495
关键词
systemic juvenile idiopathic arthritis; IL-1 inhibitors; IL-6 inhibitors; anakinra; tocilizumab; canakinumab; macrophage activation syndrome
类别
资金
- Pfizer
Systemic juvenile idiopathic arthritis (SJIA) is a disease marked with arthritis and several features of systemic inflammation including fevers, rashes, hepatosplenomegaly, lymphadenopathy, and serositis. The presentation can be variable and arthritis can be a later feature. Macrophage activation syndrome can be a life-threatening complication of this illness and requires early recognition and prompt therapy. Advancements in understanding the biology of SJIA have led to the development of cytokine-targeted therapies, mainly interleukin-1 (IL-1) and IL-6 inhibitors that have significantly improved outcomes. In this review, we provide an update on the advances in the understanding of SJIA biology and also the therapeutic options.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据